CASE REPORT article
Front. Med.
Sec. Dermatology
Volume 12 - 2025 | doi: 10.3389/fmed.2025.1647297
This article is part of the Research TopicExploring Cutaneous Drug-Related and Drug-Associated Adverse Events: From Clinical Insight to Therapeutic ManagementView all articles
Psoriasis caused by camrelizumab in a patient with esophageal cancer: a case report
Provisionally accepted
- North Sichuan Medical College, Nanchong, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Immune checkpoint inhibitors (ICIs) are an emerging treatment strategy for cancer, working by activating T cells to suppress tumor growth. However, they can cause immune-related adverse events (irAEs), including psoriasis. We report a case of a patient with esophageal cancer who developed psoriasis 6 weeks after starting camrelizumab. The condition improved following the discontinuation of camrelizumab and treatment with a topical glucocorticoid and a vitamin D3 derivative ointment.At 6-month follow-up, the patient showed no recurrence of psoriatic lesions or tumor progression.
Keywords: camrelizumab, Psoriasis, immune-related adverse effects, PD-1 inhibitor, esophageal cancer
Received: 08 Jul 2025; Accepted: 10 Sep 2025.
Copyright: © 2025 Duan, CHEN, ZHONG and XIONG. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Xincai XIONG, xiongxincai@163.com
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.